A phase 2 trial of niraparib plus bevacizumab maintenance therapy following first-line platinum-based chemotherapy with bevacizumab in advanced ovarian cancer: final analysis and overall survival results from OVARIO

By sjmartinez • July 3, 2025

Hardesty MM, Krivak TC, Wright GS, Hamilton E, Fleming EL, Belotte J, Gorman S, Compton N, Clements A, Gray HJ, Konecny GE, Moore RG, Richardson DL. A phase 2 trial of niraparib plus bevacizumab maintenance therapy following first-line platinum-based chemotherapy with bevacizumab in advanced ovarian cancer: final analysis and overall survival results from OVARIO. Gynecol Oncol. 2025 Jul 1;199:96-102. doi: 10.1016/j.ygyno.2025.06.014. Epub ahead of print. PMID: 40602355.

Tags: Bevacizumab, Hematology/Oncology, maintenance therapy, Niraparib, ovarian cancer, Publications

SGNDV-001: disitamab vedotin with pembrolizumab in HER2-expressing locally advanced or metastatic urothelial carcinoma

Powles TB, Grande E, Alimohamed N, Oliveira N, Sridhar SS, Drakaki A, Kanesvaran R, Loriot Y, Necchi A, Franco S, Jiang D, Apolinario K, Zhang[...]

Revolutionizing breast cancer treatment: the promise of antibody-drug conjugates

Alkassis S, Glaspy JA, Bardia A. Revolutionizing breast cancer treatment: the promise of antibody-drug conjugates. Clin Adv Hematol Oncol. 2025 Jul-Aug;23(5):290-299. PMID: 40728347.

A Patient’s Journey With Modern Melanoma Therapy

Black AC, Senofsky G. A Patient's Journey With Modern Melanoma Therapy. Cureus. 2025 Jun 26;17(6):e86811. doi: 10.7759/cureus.86811. PMID: 40718227; PMCID: PMC12296936.